EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)

Basit Öğe Kaydı
dc.contributor.authorPowles, T. B.
dc.contributor.authorPerez Valderrama, B.
dc.contributor.authorGupta, S.
dc.contributor.authorBedke, J.
dc.contributor.authorKikuchi, E.
dc.contributor.authorHoffman-Censits, J.
dc.contributor.authorIyer, G.
dc.date.accessioned2025-05-10T19:48:33Z
dc.date.issued2023
dc.departmentİstanbul Medeniyet Üniversitesi
dc.descriptionAnnual Meeting of the European-Society-for-Medical-Oncology (ESMO) -- DEC 01-03, 2023 -- SINGAPORE
dc.description.abstract[No abstract available]
dc.description.sponsorshipEuropean Soc Med Oncol
dc.description.sponsorshipAstellas Pharma, Inc.; Seagen Inc.
dc.description.sponsorshipAstellas Pharma, Inc. and Seagen Inc.
dc.identifier.doi10.1016/j.annonc.2023.10.347
dc.identifier.endpageS1558
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.scopusqualityQ1
dc.identifier.startpageS1557
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2023.10.347
dc.identifier.urihttps://hdl.handle.net/20.500.14730/11749
dc.identifier.volume34
dc.identifier.wosWOS:001122475400214
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofAnnals of Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titleEV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu